Vaxxinity EBITDA 2020-2023 | VAXX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Vaxxinity ebitda from 2020 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Vaxxinity ebitda from 2020 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$233.7B
Amgen (AMGN)	$153.4B
Gilead Sciences (GILD)	$148.9B
Vertex Pharmaceuticals (VRTX)	$99.4B
Bristol Myers Squibb (BMY)	$94.7B
CSL (CSLLY)	$83.8B
GSK (GSK)	$77.9B
Regeneron Pharmaceuticals (REGN)	$59B
Alnylam Pharmaceuticals (ALNY)	$56.4B
Argenex SE (ARGX)	$39B
BioNTech SE (BNTX)	$26.7B
Insmed (INSM)	$25.8B
Royalty Pharma (RPRX)	$20.2B
Biogen (BIIB)	$18.9B
Incyte (INCY)	$15.9B
Illumina (ILMN)	$15B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$14B
Ascendis Pharma (ASND)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
QIAGEN (QGEN)	$10.9B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.2B
Moderna (MRNA)	$10B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.3B
Exact Sciences (EXAS)	$7.9B
Halozyme Therapeutics (HALO)	$7.9B
Roivant Sciences (ROIV)	$7.9B